Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly’s blockbuster GLP-1 drugs dominate headlines, but its broader portfolio deserves a standing ovation for driving ...

INDIANAPOLIS, Feb. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly’s Omvoh (mirikizumab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat moderately to severely active Crohn’s disease in adults on the NHS in ...

In 2024, Eli Lilly's revenue increased by 32% year over year to $45 billion. The tirzepatide franchise contributed about $16.5 billion -- despite having been on the market for less than three years.

In 2024, Eli Lilly's revenue increased by 32% year over year to $45 billion. The tirzepatide franchise contributed about $16.5 billion -- despite having been on the market for less than three years.

In 2024, Eli Lilly's revenue increased by 32% year over year to $45 billion. The tirzepatide franchise contributed about $16.5 billion -- despite having been on the market for less than three years.